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Abstract
The inability of neutrophils to eradicate Pseudomonas aeruginosa within the cystic fibrosis (CF) airway eventually results in
chronic infection by the bacteria in nearly 80 percent of patients. Phagocytic killing of P. aeruginosa by CF neutrophils is
impaired due to decreased cystic fibrosis transmembrane conductance regulator (CFTR) function and virulence factors
acquired by the bacteria. Recently, neutrophil extracellular traps (NETs), extracellular structures composed of neutrophil
chromatin complexed with granule contents, were identified as an alternative mechanism of pathogen killing. The
hypothesis that NET-mediated killing of P. aeruginosa is impaired in the context of the CF airway was tested. P. aeruginosa
induced NET formation by neutrophils from healthy donors in a bacterial density dependent fashion. When maintained in
suspension through continuous rotation, P. aeruginosa became physically associated with NETs. Under these conditions,
NETs were the predominant mechanism of killing, across a wide range of bacterial densities. Peripheral blood neutrophils
isolated from CF patients demonstrated no impairment in NET formation or function against P. aeruginosa. However,
isogenic clinical isolates of P. aeruginosa obtained from CF patients early and later in the course of infection demonstrated
an acquired capacity to withstand NET-mediated killing in 8 of 9 isolates tested. This resistance correlated with development
of the mucoid phenotype, but was not a direct result of the excess alginate production that is characteristic of mucoidy.
Together, these results demonstrate that neutrophils can kill P. aeruginosa via NETs, and in vitro this response is most
effective under non-stationary conditions with a low ratio of bacteria to neutrophils. NET-mediated killing is independent of
CFTR function or bacterial opsonization. Failure of this response in the context of the CF airway may occur, in part, due to an
acquired resistance against NET-mediated killing by CF strains of P. aeruginosa.
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Introduction
Cystic fibrosis (CF) is the most common lethal genetic disease to
affect the non-Hispanic white population in the United States [1,2].
Despite advances in treatment [3], pulmonary complications
remain the leading cause of death [4]. While increased inflamma-
tion is present in CF infants [5], the eventual development of
chronic airway infection with Pseudomonas aeruginosa is associated
with an accelerated decline in lung function and increased
morbidity and mortality [6,7,8,9,10,11,12,13].
Neutrophils provide the first line of defense against airway
infection by killing and digesting phagocytosed bacteria and fungi.
The CF airway contains abundant neutrophils [14], which may
contribute to clearance of initial exposures to P. aeruginosa [13].
Over time, the neutrophil fails to eradicate P. aeruginosa, and the
dysregulated release of intracellular components plays a significant
role in accelerating the development of bronchiectasis. Dysfunc-
tion of the CF neutrophil occurs both as a result of the intense
inflammatory and proteolytic milieu within the CF airway, and
as a direct result of decreased cystic fibrosis transmembrane
conductance regulator (CFTR) expression within the cell
[15,16,17,18,19,20,21,22]. In particular, lack of CFTR function
has been linked to decreased phagocytic capacity via reduced
intraphagolysosomal HOCl production, resulting in defective
killing of P. aeruginosa [16,23,24]. However, other key elements of
the antimicrobial response, including reactive oxygen species
PLoS ONE | www.plosone.org 1 September 2011 | Volume 6 | Issue 9 | e23637generation via NADPH oxidase components appear normal,
independent of CFTR function in the neutrophil [25].
Failure of CF neutrophils to eradicate P. aeruginosa also results
from adaptation of the pathogen to resist host defenses within the
unique environment of the CF lung. P. aeruginosa displays
hypermutability in the CF airway [26,27], facilitating the
expression of virulence determinants postulated to contribute to
chronic infection [26,28,29,30,31,32,33,34,35]. Among these, the
development of mucoidy is one of the most commonly observed
phenotypes among CF airway isolates of P. aeruginosa, which
impairs phagocytic killing by neutrophils [36] and is linked to
chronic infection and accelerated airway injury [37,38,39,40].
The identification of neutrophil extracellular traps (NETs) as an
alternative mechanism of bacterial killing prompts careful
consideration of their role in the CF airway. NETs are
extracellular structures comprised of neutrophil chromatin com-
plexed with granule proteins [41]. NETs bind and kill pathogens
by juxtaposing microbes with neutrophil granule proteins and
histones [41,42]. The formation of NETs involves a distinct
mechanism of neutrophil death [43], though pathways not leading
to death exist [44,45]. Little is known about the signaling
mechanisms that trigger NET formation. While in early
experimental designs intact NADPH oxidase function, myeloper-
oxidase, and neutrophil elastase appeared essential [43,46,47],
early NET formation against S. aureus can occur independent of
NADPH oxidase [45]. NETs appear to play a protective role in
many infections, including appendicitis, shigellosis, Group A
Streptococcus (GAS) soft tissue infections and pharyngitis, pneumo-
coccal pneumonia, and sepsis [41,48,49]. The relevance of NETs
to human disease is supported by the finding that GAS strains that
express nucleases capable of destroying NETs display enhanced
virulence [48,49].
Many of the current assumptions concerning the role and
regulation of NETs arise from the experimental design of the
pioneering reports in this rapidly evolving field. Most studies have
utilized an activating or priming agent such as phorbol 12-
myristate 13-acetate (PMA), chemokines, or cytokines to induce
NETs [41,48,50,51,52,53], though some pathogens have been
shown to directly stimulate NET formation [45,49,54,55,56].
Initial reports suggested that NETs were fragile [41], so most
investigations employed assays with neutrophils motionless on
plates [41,48,54,56]. Recently, NETs were shown to remain intact
and bind bacteria under shear stress consistent with physiologic
flow in the microvasculature [57]; however, the capacity of NETs
to kill under the non-stationary conditions present in the
circulation or the lung has not been demonstrated ex vivo.I ti s
increasingly evident that significant variability exists between types
of bacteria with regards to their capacity to evoke NET formation
[45] and their susceptibility to NET-mediated killing [48,49].
We hypothesized that NET-mediated killing of P. aeruginosa is
impaired in the context of CF airway infection. We tested NET
formation and NET-mediated killing across a broad range of
multiplicity of infection (MOI), under conditions where the
neutrophils and P. aeruginosa are maintained stationary on a surface,
or are in suspension owing to constant motion. Under conditions
resulting in optimal NET-mediated killing, we tested the role of
CFTR in NET formation, and the effect of P. aeruginosa adaptation
over time in the CF airway on susceptibility to NET-mediated
killing. Herein we demonstrate that P. aeruginosa induces NET
formation, and is effectively bound and killed by NETs. Unlike
phagocytic killing, NET-mediated killing is not diminished in the
absence of functional CFTR. However, as P. aeruginosa adapts to the
CF airway, it appears to acquire resistance to NET-mediated killing
that is independent of alginate overproduction (i.e., mucoidy).
Materials and Methods
Ethics statement
These studies were approved by the National Jewish Health
Institutional Review Board and written informed consent
approved by the National Jewish Health Institutional Review
Board was obtained from all neutrophil donors.
Neutrophil isolation
Human peripheral blood neutrophils were isolated from healthy
volunteer donors or CF patients (confirmed by sweat chloride and
genetic testing) utilizing the plasma/Percoll method [58]. Whole
blood (40 ml) was collected from donors into 50 ml tubes
containing 4.4 ml of 3.8% citrate (Fisher Scientific). Samples were
maintained at room temperature throughout the isolation
procedure to prevent nonspecific neutrophil activation. Tubes
were centrifuged at 300 g for 20 minutes, with the centrifuge
allowed to slow without braking. The platelet-rich plasma layer
was aspirated into a fresh tube and centrifuged for 15 minutes at
2500 g; the supernatant was removed to obtain platelet-poor
plasma (PPP). To the remaining original tube contents (consisting
of erythrocytes and leukocytes), 5 ml of 6% dextran (Pharmacia)
was added, followed by sufficient 0.9% saline to produce a final
volume of 50 ml. Tube contents were mixed by gentle inversion
five times, and allowed to stand for 30 minutes at room
temperature to allow erythrocyte sedimentation. The leukocyte-
rich upper layer was carefully aspirated into a fresh 50 ml tube
and centrifuged at 275 g for 6 minutes. The resulting pellet was
resuspended in 2 ml of PPP, and transferred to a 15 ml
polystyrene tube. The leukocyte suspension was then underlayered
with 2 ml of 42% Percoll (Pharmacia) freshly prepared in PPP,
and both layers then underlayered with 2 ml of freshly prepared
51% Percoll in PPP. The resulting gradients were centrifuged for
10 minutes at 275 g. Mononuclear cells and remaining platelets,
located at the interface between the upper layer and the 42%
Percoll layer, were aspirated into a new tube using a polyethylene
transfer pipette. Neutrophils were collected from the interface
between the 42% and 51% Percoll layers. The collected
neutrophils were then washed once in PPP with centrifugation
for 6 minutes at 275 g, washed again in Krebs-Ringer phosphate
buffer (KRPD) (1.2 mM MgSO4, 120 mM NaCl, 5 mM KCl,
1 mM CaCl2, 10 mM glucose, 3 mM NaH2PO4,1 2 m M
Na2HPO4), and resuspended at a concentration of 10
7 neutro-
phils/ml in KRPD until use. This preparation method yields a
.97% pure population of neutrophils.
Media for all experiments
All experiments were performed in RPMI medium supple-
mented with 10 mM HEPES (pH 7.4) and 2% heat-inactivated
platelet poor pooled human plasma (HIPPP). HIPPP was prepared
by pooling the PPP obtained during neutrophil isolation (above)
from 5–10 donors. Approximately 300 ml of pooled PPP was
placed in a 500 ml polystyrene bottle and incubated in a 56uC
water bath for 30 minutes with swirling every 10 minutes, followed
by centrifugation at 2500g to clear precipitated proteins. Aliquots
(1 ml) of HIPPP were stored for up to 6 months at 220uC before
use. The experimental media was confirmed to contain no
detectable DNase activity, which has been detected under
experimental conditions that utilize higher concentrations of fetal
calf serum [59].
NET formation assay
During initial studies of NET formation, we observed extensive
variability in NET production by unstimulated neutrophils. This
NETs in Response to Pseudomonas aeruginosa
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interactions between neutrophils, as maintaining neutrophils in
suspension prevents significant NET formation by unstimulated
cells. Accordingly, we utilized a modification of the method of
Fuchs et al. for NET quantitation [43]. Purified human neutrophils
(10
6 in 200 ml of the media above) were treated with 25 nM PMA
(Sigma), 10 mM DPI (Sigma) or bacteria at the indicated MOI at
37uC with rotation at 8 rpm. At each time interval tested, limited
nuclease digestion was performed with micrococcal nuclease (0.5
units/ml for 10 minutes at 37uC)(Sigma). Nuclease activity was
then stopped with 5 mM EDTA (Sigma), and cellular debris
removed by centrifugation. DNA content was measured with the
Quant-iT
TM Picogreen assay (Invitrogen).
Bacteria
P. aeruginosa PAO1 was obtained from the Pseudomonas Genetic
Stock Center (East Carolina University). Deidentified, isogenic-
paired early and late clinical isolates of P. aeruginosa were obtained
from the laboratories of Michael L. Vasil, Jane L. Burns and
Samuel M. Moskowitz [13,60,61,62]. A mucA mutant of PAO1
generated by targeted disruption with a gentamicin resistance
cassette, and a transposon-generated mucA mutant of PAO1
(PW2387) was obtained from the University of Washington P.
aeruginosa mutant library [63]. All bacteria were grown on LB agar
or in LB broth. Stationary phase bacteria were utilized for all
experiments. For experiments using opsonized bacteria, PAO1
was opsonized in 0.9% saline containing 20% pooled human
serum for 30 minutes in a 37uC incubator with rotation at 8 rpm.
Opsonized bacteria were washed and resuspended twice in PBS,
and then resuspended in the experimental media (described
above). The Staphylococcus aureus strain used was a deidentified
clinical strain isolated from a CF patient by the Microbiology
Laboratory at National Jewish Health.
Fluorescence microscopy
Stationary phase P. aeruginosa PAO1 were washed with saline
and resuspended at 1610
9 CFU/ml and stained for 10 minutes at
37uC with 10 mg/ml Polymyxin B-BODIPY (Invitrogen) in saline.
Figure 1. P. aeruginosa stimulates NET formation in nonadher-
ent neutrophils. Human neutrophils suspended in media were
untreated or treated with 25 nM PMA, 10 mM DPI, or P. aeruginosa at
MOI of 0.1, 1, 10, or 100. NET formation was measured at 30-minute
intervals by DNA released (ng per 10
6 PMN). Neutrophils were isolated
from healthy donors (n=3) with samples performed in duplicate; error
bars represent SEM. *** = p,0.001 by two-way ANOVA with
Bonferroni’s post-test compared to untreated control.
doi:10.1371/journal.pone.0023637.g001
Figure 2. NET formation and binding of P. aeruginosa by nonadherent neutrophils. Panels A and B: Bacterial cells of strain PAO1 labeled
with polymyxin B-BODIPY were incubated with isolated human neutrophils (MOI of 10) for 2 hours with (Panel B) or without (Panel A) DNase. NETs
were then stained with the cell-impermeant DNA binding dye, Sytox Orange. In the presence of DNase, NETs are seen to be completely degraded.
Panels C and D present the results of a similar experiment performed at a higher ratio of bacteria to neutrophils (MOI of 100), to highlight the
physical association of bacteria with NETs.
doi:10.1371/journal.pone.0023637.g002
NETs in Response to Pseudomonas aeruginosa
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for 120 minutes at 37uC with rotation at 9 rpm in RPMI medium
supplemented with 10 mM HEPES (pH 7.4) and 2% HIPPP.
Extracellular DNA was stained with the Sytox Orange (Invitrogen)
at a concentration of 0.1 mM. The cell suspension was imaged in
micro chamber slides (Ibidi) or, after fixation with 4% parafor-
maldehyde (Sigma), on glass slides. Microscopy was performed
with a Zeiss Axiovert 200M with Slidebook 5 software (Intelligent
Imaging Innovations).
Bacterial killing assays
Using bacterial killing assays in plates [41,48,54], we found that,
without inhibition of phagocytosis with cytochalasin D, a minor
fraction of P. aeruginosa killing was NET-mediated (data not
shown). We then investigated conditions that maximized NET
killing without inhibition of phagocytosis. We found that the
majority of killing was attributable to NETs if the neutrophils and
bacteria remained in suspension by continuous rotation. For
plated killing assays, 10
6 neutrophils in 200 ml of media (above)
were seeded into 96 well plates. Samples were untreated or treated
with 25 nM PMA (Sigma) for 105 minutes at 37uC, with or
without DNase I at 100 units/ml (Worthington) to degrade NETs.
Phagocytic killing was inhibited in some samples by the addition of
100 mg/ml cytochalasin D (Sigma) for 15 minutes before the
addition of bacteria. Bacteria at the indicated MOI were added
and the plates centrifuged at 800 g for 10 minutes. After one hour
at 37uC, neutrophils and clumped NETs were disrupted by the
addition of 0.01% Triton X-100 and three passes through a 25
gauge needle. Following serial dilution, bacteria were plated on LB
plates for enumeration of colonies. Suspension killing assays were
performed similarly, except assays were performed in microfuge
tubes with rotation at 8 rpm, and no centrifugation was
performed. Because neutrophils incapable of killing appeared to
enhance bacterial recovery, ‘‘zero killing’’ was defined by control
samples consisting of neutrophils treated with DNase I (100 units/
ml) to inhibit NET-mediated killing, with and without cytochalasin
D (100 mg/ml) as an inhibitor of phagocytic killing. Killing by
NETs was determined by subtracting the extent of killing in the
presence of DNase I (i.e. phagocytic killing) from total killing.
Figure 3. NET-mediated killing of P. aeruginosa is most effective
for nonadherent neutrophils. Panel A: Non-opsonized or opson-
ized bacterial cells of strain PA01 were juxtaposed to neutrophils on the
surface of a plate by centrifugation (MOI of 0.01). Neutrophils were
untreated or exposed to 25 nM PMA for 2 hours to maximize NET
formation prior to the addition of bacteria. *** = p,0.001 and NS =
p.0.05 by ANOVA with Bonferroni’s post-test. Panel B: This killing
assay was performed with continuous rotation of the neutrophils.
Under these conditions, virtually all killing is attributable to NETs.
Neutrophils were isolated from healthy donors (n=5) with samples
performed in duplicate; error bars represent SEM. All comparisons were
non-significant, with p.0.05 by ANOVA with Bonferroni’s post-test.
doi:10.1371/journal.pone.0023637.g003
Figure 4. NETs kill P. aeruginosa in suspension across a wide
range of MOI. Panel A: The effect of MOI on NET-mediated killing
was tested with neutrophils and PAO1 stationary on a plate, as depicted
in Figure 3A. Over a 3-log range of MOI, NET-mediated killing
represented a very small fraction of total killing. *** = p,0.001 and
NS = p.0.05 by ANOVA with Bonferroni’s post-test. Panel B: With
PAO1 and neutrophils in suspension, NET-mediated killing accounted
for nearly all killing over a 5-log range of MOI. The lowest MOI tested
trended towards greater efficiency of NET-mediated killing. Neutrophils
were isolated from healthy donors (n=5) with samples performed in
duplicate. Differences in total killing and NETs killing at each MOI were
not significant.
doi:10.1371/journal.pone.0023637.g004
NETs in Response to Pseudomonas aeruginosa
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Data were analyzed with GraphPad Prism 4.0 software
(GraphPad Software, Inc.) with use of Student’s t-test or ANOVA
with Bonferroni’s post-test as appropriate.
Results
P. aeruginosa induces NET formation by neutrophils in
suspension
While P. aeruginosa has been noted to induce NET formation
[45,64], systematic studies with this bacterium are not available
[49,51,56,65,66]. To date, in vitro quantification of NET formation
has nearly always been performed with neutrophils seeded onto
surfaces; however, we have observed a high background of non-
specific NET formation under those conditions (data not shown).
With the cells in suspension, we evaluated the capacity of
unprimed neutrophils to spontaneously form NETs, and the
response of neutrophils to PMA (a potent inducer of NETs [41]),
diphenyleneiodonium (DPI) (an inhibitor of NETs [43]), and P.
aeruginosa strain PAO1 across a four-log10 range of MOI [67].
Under these conditions, little release of NETs was detected over 2
hours by untreated neutrophils (Figure 1). P. aeruginosa strain
PAO1 effectively stimulated NET formation in a bacterial density-
dependent fashion (Figure 1).
NET-mediated killing of P. aeruginosa by neutrophils in
suspension
NET-mediated killing occurs through binding of pathogens to
strands of DNA to facilitate direct contact of the microbe with
antimicrobial neutrophil granule products [41]. Fluorescence
microscopy was utilized to evaluate physical entrapment of P.
aeruginosa within NETs. Neutrophils suspended in media were
exposed to fluorescently labeled P. aeruginosa strain PAO1 at an
MOI of 10 and stained with a cell-impermeant DNA stain,
revealing abundant NETs formation (Figure 2A). Confirmation
that the observed structures represent NETs was obtained by their
absence when the identical experiment was conducted in the
presence of DNase (Figure 2B) [41]. Similar experiments
performed at an MOI of 100 to optimize visualization of the
NETs and bacteria demonstrate physical entrapment of PAO1
within NETs (Figure 2C and 2D).
Close physical association between pathogens and neutrophils
on a motionless surface is the standard experimental design for
assays of NET-mediated killing [41,48,54]. However, surface
adherence of neutrophils can activate integrin-mediated signaling
pathways, and modify a broad range of responses [68]. We
investigated the role of surface contact on killing of P. aeruginosa.
Using a typical assay for NET-mediated killing, in which bacteria
and neutrophils are layered together on a surface by centrifuga-
tion, phagocytic killing (i.e. DNase resistant) is the primary
mechanism by which neutrophils kill PAO1, evidenced by the
fact that only a small fraction of total killing is attributable to
NETs (Figure 3A). In contrast, when neutrophils and P. aeruginosa
are incubated together in a suspended state, nearly all killing is
NET-mediated (Figure 3B). Non-specific opsonization of bacteria
did not enhance non-NET-mediated killing by stationary
neutrophils (Figure 3A), and likewise was not required for NET-
mediated killing in suspension (Figure 3B). As PAO1 stimulates
NET formation (Figure 1), NET-mediated killing of the bacteria
can occur in the absence of additional activation of the neutrophil
(Figure 3B). Greater NET-mediated killing can be achieved by
inducing maximal NET release in response to PMA, followed by
introduction of P. aeruginosa (Figure 3B). Of note, this strong
dependence on NET-mediated killing in the suspended state
occurred optimally under conditions in which a low concentration
of HIPPP (2%) was present in the media. Previously, it has been
reported that higher concentrations of serum inhibit NET
formation in a concentration-dependent fashion [43], and we
confirmed in this system that virtually no killing of P. aeruginosa in
suspension is NET-mediated when higher concentrations of serum
are present (data not shown).
NET-mediated killing of P. aeruginosa occurs over a broad
range of MOI
Some studies suggest that phagocytic killing of P. aeruginosa and
other bacteria by neutrophils varies in efficiency with changes in
MOI [69,70], though this has been debated [32]. Thus, we tested
the effect of MOI on P. aeruginosa PAO1 killing under conditions
optimized for either phagocytic or NET-mediated killing.
Neutrophils stationary on a surface (see Methods) were activated
with PMA to induce maximal NET formation, and were then
incubated with PAO1 at MOI from 0.1 to 10. NET-mediated
killing was significantly less than phagocytic killing for all bacteria
Figure 5. Neutrophils isolated from CF patients form NETs that
effectively kill P. aeruginosa. Panel A: Neutrophils from healthy
volunteers (filled boxes) or CF patients (hatched boxes) were
unstimulated (PMN), treated with an inhibitor of NET formation (DPI),
treated with a stimulant of maximal NET formation (PMA), or exposed to
PAO1 at the indicated MOI. Released NET-associated DNA was
quantitated after a 120-minute exposure. There were no significant
differences in NET formation between neutrophils isolated from healthy
volunteers and CF patients. Panel B: CF neutrophil NET-mediated
killing of bacterial cells of strain PAO1 was performed in suspension as
in Figure 3B. Effective killing of PAO1 was observed in the absence of
additional stimulation, and was significantly enhanced by pre-treatment
with PMA to stimulate maximal NET formation. For both panels,
neutrophils were isolated from CF patients (n=5) with samples
performed in duplicate; error bars represent SEM. * = p,0.05 and
** = p,0.01 by ANOVA with Bonferroni’s post-test.
doi:10.1371/journal.pone.0023637.g005
NETs in Response to Pseudomonas aeruginosa
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mediated killing was most efficient at the lowest MOI tested (0.01),
although greater absolute numbers of bacteria were killed at
higher MOIs (Figure 4B). As seen in Figure 3B, NET-mediated
killing was the predominant mechanism by which neutrophils
killed PAO1 under conditions of constant motion.
Neutrophils isolated from CF patients display normal
NET-mediated killing of P. aeruginosa
Recently, defects in phagocytic killing of P. aeruginosa have been
linked to decreased HOCl production within the neutrophil
phagolysosome, as a direct result of absent or reduced CFTR
function [16,23,24]. NET production and bactericidal activity of
neutrophils isolated from CF patients were evaluated separately in
response to P. aeruginosa. CF neutrophils had nearly identical
baseline NET-formation, response to PMA, and concentration-
dependent response to P. aeruginosa as neutrophils isolated from
healthy donors (Figure 5A). In addition, the NETs formed by CF
neutrophils effectively killed PAO1 (Figure 5B).
Clinical strains of P. aeruginosa develop resistance to
NET-mediated killing within the CF airway
To better evaluate the significance of NET-mediated killing of
P. aeruginosa in the CF airway, we examined whether clinical
isolates of P. aeruginosa were effectively killed by this mechanism.
Nine well-characterized paired isolates of P. aeruginosa from CF
patients were utilized (Tables 1 and 2), with an ‘‘early’’ isolate
recovered at or shortly after initial infection, and a second ‘‘late’’
isogenic isolate recovered at a later date [13,60,61,62]. The mean
interval between isolation of the strains was 10.6 years (range
0.25–18 years). In 8 of 9 pairs, the early isolate had a non-mucoid
phenotype, while all of the late isolates had converted to a mucoid
phenotype. In addition to mucoidy, changes in colony size, shape
and color were evident, along with acquisition of changes in
resistance to standard anti-pseudomonal antibiotics (Tables 1 and
2). Growth rates also demonstrated considerable divergence
between early and late isolates, as 7 of 9 late strains grew more
slowly under the conditions tested, with longer time in lag phase,
and greater time until mid-log phase (Table 1).
Early CF isolates were killed by NETs with a similar efficiency
as PAO1 (Figure 6A). However, in 7 of 9 isolates, a significant
reduction in NET-mediated killing was observed for the late
isolates. In aggregate, there was a 41.5% reduction in the
percentage of P. aeruginosa killed via NETs by the late isolates
compared to the early isolates (p,0.001)(Figure 6B). A clinical CF
isolate of S. aureus had a relatively low rate of NET-mediated
killing relative to P. aeruginosa. To assess whether the reduced
susceptibility of the late isolates to killing by NETs was explained
solely by excess exopolysaccharide production (which character-
izes the mucoid phenotype), we tested two independently derived
mucA mutants of PAO1, which overexpress alginate, for their
susceptibility to NET killing. Neither of the mucA mutants
displayed a statistically significant difference in sensitivity to killing
Table 1. Growth characteristics of early and late CF clinical isolates of Pseudomonas aeruginosa.
Strain Morphology Growth
ID number Isolate
1
Isolation
Date Mucoid Colony Size Colony Shape Color
Lagtime
2
(min) V50
3 (min)
DNA
release
4 (ng/
10
5 bacteria)
AMT0009 E Mar-97 N large irregular 520 674 7.260.8
L Apr-08 Y small round translucent 848 1182 10.861.0
NS
AMT0105 E Sep-93 N very small round yellowish tan 569 696 26.361.9
L Jul-06 Y small round pink & tan 621 875 43.361.5
NS
AMT0145 E Jan-90 N small irregular 646 960 14.260.8
L Jan-02 Y small round 936 1504 16.160.5
NS
AMT0147 E Feb-95 N small to medium round 505 591 12.4+1.1
L Jan-96 Y very small round pinkish 630 824 11.963.4
NS
AMT0027 E Jun-97 N small Irregular pinkish tan 510 780 7.060.8
L Aug-09 Y small round tan 555 764 13.962.4
NS
AMT0058 E Dec-94 N small round slightly metallic 732 1016 7.161.1
L Oct-09 Y small round pinkish tan 838 1056 13.560.6
NS
AMT0059 E Sep-91 Y small round pinkish tan 720 1003 12.460.8
L Aug-09 Y small round pinkish tan 600 831 17.3+0.6
NS
AMT0294 E Apr-96 N small round rings 805 1053 15.260.6
L Aug-09 Y small round pinkish tan 615 1150 12.860.4
NS
CO CF1 E Feb-86 N small round yellow 420 570 15.160.4
L May-86 Y small round yellow 750 1012 12.661.1
NS
PA01 N/A N/A N small round yellow 482 568 14.660.8
1Isolate: E indicates an isolate recovered early after infection, L indicates isolate recovered later in the life of the patient.
2Lagtime: Time (minutes) from start of culture to start of log phase growth.
3V50: Time (minutes) from start of culture to midpoint of log phase growth.
4DNA release: Quanitity of DNA released from each isolate under the conditions tested in the NET-induced killing assay.
NSNot Significant compared to isogenic early isolate by Wilcoxon 2-sample test.
doi:10.1371/journal.pone.0023637.t001
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Extracellular DNA release, a virulence mechanism for P. aeruginosa,
was also tested. Overall, the release of DNA from the strains was
low, under the conditions of the NET-mediated killing assay. In 6
of 9 pairs, the late isolate released greater DNA, however, this
difference did not reach statistical significance in any of the pairs
studied (Table 1).
Discussion
Neutrophil extracellular traps are a recently described mecha-
nism by which neutrophils kill a variety of pathogens. However,
significant variability appears to exist in the relative susceptibility
to NET-mediated killing by clinically important microbes, and the
relative biologic roles of NET versus phagocytic killing have yet to
be clearly elucidated in health and disease (i.e., in specific clinical
infections or within specific anatomic compartments). Herein, we
demonstrate that P. aeruginosa induces formation of NETs and is
susceptible to NET-mediated killing ex vivo under specific
conditions. Under conditions typically used to study NETs, where
bacteria and neutrophils were layered together on a motionless
surface, we found that phagocytic killing of P. aeruginosa was the
predominant response. In contrast, under conditions in which the
bacteria and neutrophils are maintained in suspension with
constant motion and mild shear forces, nearly all killing of P.
aeruginosa was NET-mediated. To our knowledge, these experi-
mental test conditions have not previously been examined. Under
these conditions, NET-mediated killing was efficient even with a
very low ratio of P. aeruginosa to neutrophils and was not dependent
on opsonization of the bacteria. This method was optimized to test
the parameters of NET-mediated killing of P. aeruginosa; optimal
NET-mediated killing of other pathogens may require different
experimental conditions.
In the context of CF lung disease, we explored the possibility
that CF neutrophils might fail to produce effective NETs,
prompted by observations that a number of neutrophil responses
are abnormal in the setting of non-functional CFTR
[16,17,18,19,20,21,22,23]. Specifically, previous reports have
indicated that CFTR deficiency results in reduced phagolysosomal
function in neutrophils and macrophages, and impaired phago-
cytic killing of P. aeruginosa [16,23,56,71]. In contrast, our results
indicate that CF neutrophils produce functional NETs comparable
to those of neutrophils with functional CFTR. Thus, NET-
mediated killing is a CFTR-independent arm of the innate
immune response that may assume greater importance in CF
patients. Despite many reports identifying impaired response by
CF neutrophils, these cells clearly have substantial antimicrobial
capabilities, as bacterial infections outside the airway are not a
feature of the disease. Our findings suggest that NET-mediated
killing is fully functional in CF patients, and thus may account for
the general absence of invasive infection despite a massive
bacterial burden within the CF airway.
Our data suggest a role for NET-mediated clearance of initial P.
aeruginosa infection in healthy individuals, and possibly in the early
stages of CF lung disease. Episodic exposure of humans to P.
aeruginosa is likely a common occurrence. Even within the CF
airway, P. aeruginosa is often cleared effectively, and progression to
chronic infection may not occur for years [13]. One possibility is
that resident macrophages within the lung could be responsible for
this initial clearance. However, another possibility is that NET-
mediated killing by neutrophils may account for early clearance.
Conditions that favor NET-mediated killing are likely present
Table 2. Antibiotic Susceptibility of early and late CF clinical isolates of Pseudomonas aeruginosa.
Strain Antibiotic Susceptibility
1
ID number Isolate
2 Amikacin Aztreonam Cefepime Ceftazidime Ciprofloxacin Meropenem Pip/Tazo Tobramycin Trimeth/Sulfa
AMT0009 E R( .256) R (.256) S (6) S (0.5) R (32) R (256.1) S (,4) R (32)
L R( .256) R (.256) S (6) S (0.5) R (32) R (256.1) S (,4) R (32)
AMT0105 E SS R
L S( 4 ) R( .256) R (.256) I (1.5) S S (2)
AMT0145 E S (1) R (32) I (16) S (4) I (2) S (4) R (256) S (0.24) R (128)
L I (32) R (32) I (16) R (8) I (8) S (2) R (16)
AMT0147 E R (8) S (2) R (4)
L RR R
AMT0027 E S (1) S (0.9) S (4) S (1) S (1) S (0.49) S (3.9) S (0.9) S (2)
L S (4) S (4) R (32) S (2) I (2) I (8) R (256) S (0.9) R (16)
AMT0058 E RS R
L S (16) R (32) R (32) I (16) R (4) I (8) R (256) R (128) R (8)
AMT0059 E S (2) I (16) S (8) S (4) S (1) S (1) S (2) S (0.9) R (4)
L S (4) I (16) S (8) S (4) I (2) R (16) S (8) S (0.9) S (2)
AMT0294 E S (4) R (32) S (8) S (8) S (0.5) S (2) I (32) S (0.5) R (16)
L S (8) S (8) I (16) I (16) S (0.5) S (1) S (2) S (4)
CO CF1 E SS S S
L SS S S
PA01 N/A SS SS S S SS S
1Antibiotic susceptibility: R= resistant, I=intermediate, S= sensitive, (minimum inhibitory concentration).
2Isolate: E indicates an isolate recovered early after infection, L indicates isolate recovered later in the life of the patient.
doi:10.1371/journal.pone.0023637.t002
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motion, and environmental exposures typically involve small
inocula of bacteria with limited direct contact with neutrophils, in
the presence of low plasma concentrations and without effective
opsonization [72]. Consistent with this premise, our results
indicate that P. aeruginosa strains isolated from CF airways early
in the course of infection are effectively killed by NETs.
Strong evidence indicates that neutrophil defenses ultimately fail
as CF lung disease progresses and P. aeruginosa infection becomes
persistent. For CF patients, inhaled DNase therapy improves lung
function and reduces infectious exacerbations [4,73,74]. Since
DNase disrupts killing by NETs [41], these results support the
conclusion the NET-mediated killing is not effective within the
airway of CF patients who have established infection. Given the
evidence suggesting that NETs do not facilitate bacterial clearance
later in the course of CF, NET formation may actually be
detrimental by promoting hyperviscosity of airway secretions,
release of neutrophil proteases, and development of P. aeruginosa
biofilms [61,75].
One factor which could contribute to ineffective NET-mediated
killing within the CF airway is acquired P. aeruginosa resistance to
this arm of innate host defense. The hypermutability of P.
aeruginosa within the CF airway is well-described and it is not
surprising that in this intense inflammatory environment, mutants
with increased resistance to NETs would emerge [26,28,29,30,31].
We tested the capacity of CF strains of P. aeruginosa to acquire
resistance to NET-mediated killing. Using paired isogenic clinical
isolates of P. aeruginosa, we showed that decreasing susceptibility to
NET-mediated killing evolves over time in the CF airway. The
development of mucoidy (i.e. increased alginate production) is an
acquired P. aeruginosa virulence factor that is closely associated with
acceleration of CF lung disease [37,38,39,40]. Among the nine
pairs of isolates tested, conversion to a mucoid phenotype
coincided with a decline in susceptibility to NETs, raising the
possibility that increased alginate production decreases interac-
tions with NETs, or otherwise interferes with killing by NET-
associated granule proteins. However, two independently derived
mucA mutants of PAO1 failed to display the NET resistance seen
Figure 6. P. aeruginosa acquires resistance to NET-mediated killing in the CF airway. Panel A. Neutrophils were stimulated with PMA to
induce maximal NET formation and were then exposed to isogenic clinical strains of P. aeruginosa isolated from CF patients around the time of the
first positive culture (‘‘Early’’) or a mean of 10.6 years later (‘‘Late’’). * = p,0.05, ** = p,0.01, and ***=P,0.001 by Student’s t-test comparing early
strain killing versus late strain killing for each pair of isolates. Neutrophils were isolated from healthy donors (n = $4 for each set) with samples
performed in duplicate and error bars represent SEM. Total and NET-mediated killing were determined as in Figure 3. Panel B. Aggregate analysis of
the data in Panel A demonstrates a significant resistance to NET-mediated killing acquired by the Late isolates when compared to Early isolates, or
laboratory-adapted strain PAO1. * = p,0.05, ** = p,0.01, and ***=P,0.001 by ANOVA with Bonferroni’s post-test. Panel C. Isolated human
neutrophils were stimulated with PMA as for Panel A, and exposed to P. aeruginosa PAO1 or two independently derived mucA mutants of PAO1,
PW2387 (University of Washington Pseudomonas transposon mutant library) or MV mucA (targeted gentamicin cassette disruption from the
laboratory of Michael Vasil) with assessment of total and NET-mediated killing. Neutrophils were isolated from healthy donors (n = $5) with samples
performed in duplicate. Differences between samples in NET-mediated or total killing were not significant by Student’s t-test.
doi:10.1371/journal.pone.0023637.g006
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charide production alone does not explain this phenotype.
Presumably, increased expression of other, as yet unidentified,
determinants may act either independently or concurrently with
increased alginate production to mediate NET resistance. Several
pathogens possess specific mechanisms that disrupt NET-mediated
killing, including Streptococcus pneumoniae and GAS, which produce
nucleases that degrade NETs [48,49]. In addition, capsule
formation, in concert with D-alanylation of lipoteichoic acids,
enhances resistance of S. pneumoniae to NET-mediated killing [76].
GAS strains expressing the M1 protein resist NET-mediated
killing by virtue of their resistance to the human cathelicidin
peptide LL-37, an important antimicrobial component of NETs
[77]. P. aeruginosa, with its extremely large genome, is capable of
tremendous versatility and environmental adaptability [78]. It
encodes deoxyribonucleases, and the possibility exists that these, or
related enzymes, could act on NETs [79], as well as yet
undescribed mechanisms of disrupting NET-mediated killing.
Although not tested here, extrinsic features of the CF airway could
also contribute to ineffective NET function in the setting of
chronic P. aeruginosa infection. The CF airway is a complex
environment characterized by altered airway mucus, high levels of
proteases, large amounts of neutrophil-derived DNA and F-actin,
and abundant P. aeruginosa [80,81,82,83,84]. One or more of these
features may disrupt NET killing by preventing NET formation,
disassembling or altering the antibacterial components of NETs,
preventing physical interaction between P. aeruginosa and NETs, or
competing for binding sites on NETs.
We postulate that NETs contribute to early clearance of P.
aeruginosa from the CF airway, but that, later in the disease,
features of the CF airway or an adaptation of the organism render
NETs ineffective, and possibly detrimental. If in fact NET-
mediated killing is effective in the initial contact between P.
aeruginosa and neutrophils suspended within the CF airway
secretions, this has important implications both for development
of new therapies and for early CF airway disease. This notion may
also help guide the use of inhaled DNase in other lung conditions
for which benefit might be assumed based on results in CF
patients. For example, disruption of effective NET killing could
explain the increased rates of infection reported with DNase use in
non-CF bronchiectasis [85]. Understanding the role of NETs in
controlling P. aeruginosa at different stages of airway infection is
particularly important given ongoing clinical trials evaluating the
use of this agent in very young children [86], and in devising
strategies to prevent initial infection by enhancing host defenses.
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